ERBB2 and neoplasm: Further, when assessed within each tumor subtype group separately, the 19 CNIs plus clinical covariates (age of diagnosis, lymph node status, tumor size) showed improved prognostication across all subtypes (Figure 3C-F) compared with the clinical model: LUM A (C-Index  =  0.71 vs. 0.63, p = 0.047), LUM B (C-Index  =  0.71 vs. 0.50, p = 0.002), any HER2+ (C-Index  =  0.78 vs. 0.64, p = 0.014), and TNBC (C-Index  =  0.72 vs. 0.64, p = 0.046).